EP854 How did to improve the overall survival of patients with advanced serous ovarian cancer

Introduction/Background At present, there are numerous confirmed data on multitarget effect of indole-3-carbinol (I3C) and epigallocatechin-3-gallate (EGCG) against tumors of different origin. The aim was to study the effectiveness of combined therapy for patients with ovarian cancer (OC) when I3C and I3C with EGCG are included in its scheme. Methodology The study included 284 patients with an ascitic form of advanced serous OC. All of them underwent combined treatment: polychemotherapy (TP, TC, DC) and cytoreductive surgery. At the same time, treatment with neoadjuvant chemotherapy (NACT) was provided in the 1st (n=46), the 2nd (n=76) and the 3rd (n=42) groups and prolonged (60 months) usage of I3C (for the 1st group) and its combination with EGCG (for the 2nd, 3rdgroups). In addition, prolonged polychemotherapy (PPCT) was given in the 3rd group. Two groups of treatment-naive patients (without I3C, EGCG) were taken as control arm: in the 1st group (n=40) treatment included operation+6 courses of adjuvant chemotherapy (ACT); the 2nd group (n=80) was treated by NACT+operation+6 courses of ACT. The observation period was 60 months. Results The overall survival (OS) in the 1st and 2nd studies groups were higher than in the control’s groups, amounted to 65.2% and 63.2%, against 40% and 36.3%, respectively. OS in 3rd studies group achieved of 71.4%, as was as a longer progression-free survival (PFS) a median was of 48.5 months. In the 1st and 2nd studies group the median of PFS were of 39.5 and 42.5 months, in the control’s groups were 24.5 and 22 months. Conclusion We result that the usage of drugs with multitarget effects (I3C, EGCG) in addition to standard therapy of OC increased its effectiveness by forming conditions (increasing the efficacy of NACT, maintaining the sensitivity of the tumor to first-line of PCT, reducing the number of ascites relapses) to achieve a longer duration PFS, OS. Disclosure Nothing to disclose.